粒细胞集落刺激因子给药时机对不同移植物类型成人急性髓系白血病异基因造血细胞移植结局的不同影响
该回顾性研究基于日本数据库纳入2013至2022年间9766例成人急性髓系白血病患者,按移植物类型分为骨髓移植3248例、外周血干细胞移植3066例和单份脐血移植3452例,评估粒细胞集落刺激因子(G-CSF)使用及其时机对移植后结局的影响。多因素分析显示G-CSF加速所有移植物类型的中性粒细胞恢复,但增加II-IV级急性移植物抗宿主病(GVHD)风险,仅在脐血移植中显著改善总生存和无白血病生存。
要点
- G-CSF加速骨髓移植、外周血干细胞移植和脐血移植后的中性粒细胞恢复。
- G-CSF在所有移植物类型中均与II-IV级急性GVHD风险升高相关。
- G-CSF仅在脐血移植中显著改善总生存和无白血病生存。
核心结论
- G-CSF加速所有移植物类型的中性粒细胞恢复并增加II-IV级急性GVHD风险,但仅在脐血移植中显著改善生存结局。
- 因此,成人急性髓系白血病脐血移植应考虑常规使用G-CSF。
研究设计与样本
- 回顾性评估2013至2022年间日本数据库9766例成人急性髓系白血病患者。
- 按移植物类型分三个队列:骨髓移植3248例、外周血干细胞移植3066例、单份脐血移植3452例。
主要发现
- 多因素分析显示G-CSF给药显著加速骨髓移植、外周血干细胞移植和脐血移植后的中性粒细胞恢复。
- G-CSF给药与所有移植物类型中II-IV级急性GVHD风险升高相关。
- G-CSF给药在骨髓移植和脐血移植患者中增加总体慢性GVHD发生率,但在外周血干细胞移植患者中未观察到。
- G-CSF给药仅在脐血移植后显著改善总生存和无白血病生存。
- 与晚期(第5-10天)开始G-CSF相比,早期(第0-4天)开始无论移植物类型均未带来造血恢复获益;晚期开始与脐血移植患者II-IV级急性GVHD风险降低及更好的总生存和无白血病生存显著相关。
关键数值与推荐
- G-CSF给药显著加速骨髓移植、外周血干细胞移植和脐血移植后的中性粒细胞恢复。
- G-CSF给药与所有移植物类型中II-IV级急性GVHD风险升高相关。
- G-CSF给药在骨髓移植和脐血移植患者中增加总体慢性GVHD发生率,但在外周血干细胞移植患者中未观察到。
- G-CSF给药仅在脐血移植后显著改善总生存和无白血病生存。
- 与晚期(第5-10天)开始G-CSF相比,早期(第0-4天)开始无论移植物类型均未带来造血恢复获益;晚期开始与脐血移植患者II-IV级急性GVHD风险降低及更好的总生存和无白血病生存显著相关。
临床怎么用
- 作者认为,成人急性髓系白血病脐血移植应考虑常规使用G-CSF。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We retrospectively evaluated the impacts of using granulocyte colony-stimulating factor (G-CSF) and its timing on posttransplant outcomes for 9766 adults with acute myeloid leukemia (AML) between 2013 and 2022 using a Japanese database. We separately evaluated three distinct cohorts based on graft type: 3248 received bone marrow transplantation (BMT), 3066 received peripheral blood stem cell transplantation (PBSCT), and 3452 received single-unit cord blood transplantation (CBT). Multivariate analysis showed that G-CSF administration significantly accelerated neutrophil recovery after BMT, PBSCT, and CBT. However, it was associated with a higher risk of grades II-IV acute graft-versus-host disease (GVHD) across all graft types. Moreover, an increased incidence of overall chronic GVHD was observed with G-CSF administration in BMT and CBT patients, but not in PBSCT patients. G-CSF administration significantly improved overall survival (OS) and leukemia-free survival (LFS) only following CBT. Regarding the timing of G-CSF, in comparison with late initiation of G-CSF (Days 5-10), early initiation (Days 0-4) did not provide benefits for hematopoietic recovery regardless of graft type. In contrast, late initiation was significantly associated with a lower risk of grades II-IV acute GVHD and better OS and LFS in CBT patients. These data demonstrated that G-CSF administration accelerated neutrophil recovery and increased the risk of grades II-IV acute GVHD across all graft types, but significantly improved survival outcomes but only following CBT. Therefore, routine use of G-CSF should be considered for CBT in adult patients with AML.
引用
- Konuma T, Kameda K, Morita K, et al. Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type. Am J Hematol. 2024. PMID: 39564683. doi:10.1002/ajh.27521
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。